This bill adds a new section to chapter 70.41 RCW that, beginning January 1, 2027, requires every Washington hospital that operates an emergency department to maintain a supply of rabies medication for postexposure prophylaxis sufficient to provide a first dose, as medically indicated, at patient arrival. Hospitals must arrange for any additional doses needed to complete the course either by keeping stock on the premises or by making alternative arrangements so the medication is available in a timely manner. The change is a new statutory requirement (a procedural/operational obligation on hospitals) rather than a new crime or a penalty change. The extracted text does not include enforcement mechanisms, penalties, funding or reimbursement information, definitions of key terms (for example "rabies medication for postexposure prophylaxis," "first dose," "as medically indicated," or "timely manner"), or specific clinical protocols. The bill is identified as H-2503.1 / House Bill 2434 (69th Legislature, 2026 Regular Session), was read first time in the House on January 13, 2026, and was referred to the Health Care & Wellness committee; sponsors listed are Representatives Shavers, Parshley, and Hill.

If this law takes effect on January 1, 2027, every hospital in Washington with an emergency department will have to be ready to give a patient the first dose of rabies postexposure treatment when they arrive and must ensure the rest of the course can be obtained either by keeping additional doses on site or by arranging timely access to them. That shifts a clear new operational responsibility to hospitals and gives them two options for meeting it: stock the medication or set up a reliable way to get it quickly. The most affected parties are hospitals with emergency departments, which will likely face added costs and logistical work to purchase, store, and track rabies postexposure medication or to negotiate and maintain timely supply arrangements. Important details are missing from the bill text provided, including who pays for the medication, what counts as “timely” or “as medically indicated,” which specific products or protocols apply, and how compliance would be enforced.